Welcome to our dedicated page for Haleon SEC filings (Ticker: HLN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Haleon plc (HLN) SEC filings page provides access to the company’s regulatory disclosures as a foreign private issuer listed on both the London Stock Exchange and the New York Stock Exchange. Haleon files annual reports on Form 20-F and submits current reports on Form 6-K under the Securities Exchange Act of 1934. These filings cover topics such as trading statements, total voting rights and capital, board and committee changes, and transactions by persons discharging managerial responsibilities (PDMRs).
Recent 6-K filings include announcements on Haleon’s Q3 trading statement, regular updates on total voting rights and capital, and detailed notifications of share transactions under the company’s share reward plans by senior managers. Other filings describe governance developments, such as the appointment of a new Chair, changes to the Senior Independent Director role and committee memberships, and the evolution of Haleon’s operating model, including the creation of six Operating Units and new executive roles like Chief Growth Officer and Chief Transformation Officer.
Many filings contain an "About Haleon" section that reiterates the company’s profile as a global leader in consumer health with a portfolio spanning Oral Health, Vitamins, Minerals and Supplements (VMS), Pain Relief, Respiratory Health, Digestive Health and Therapeutic Skin Health and Other, along with examples of long-standing brands such as Advil, Centrum, Otrivin, Panadol, parodontax, Polident, Sensodyne, Theraflu and Voltaren.
On this page, investors can review Haleon’s SEC submissions as they are made available from EDGAR, while AI-powered tools on the platform can help summarise key points, highlight changes over time and surface information on areas such as capital structure, insider share dealings disclosed as PDMR transactions, and updates to the company’s governance and operating model.
Haleon plc reports its share capital and voting rights position as at 31 March 2026. The company has issued 8,931,093,261 ordinary shares of £0.01 each, of which 12,548,735 are held in treasury. This leaves 8,918,544,526 ordinary shares carrying voting rights, which shareholders should use as the denominator when assessing whether they must notify holdings or changes in holdings under the FCA's Disclosure Guidance and Transparency Rules.
Haleon plc reports that it purchased 8,939,706 ordinary shares of £0.01 each for cancellation under its share buyback programme announced on 12 March 2026. The purchases took place between 23 and 27 March 2026 across the London Stock Exchange, CBOE (UK) and Aquis at prices between 353.7000p and 373.0000p per share.
After settlement, Haleon’s registered share capital is 8,932,831,335 ordinary shares, of which 12,548,735 are held as treasury shares. The number of ordinary shares with voting rights is now 8,920,282,600, which shareholders may use for disclosure thresholds under the FCA’s Disclosure Guidance and Transparency Rules.
Haleon plc reported that Chief Executive Officer Brian McNamara received vesting of share awards on 23 March 2026 under the Haleon Performance Share Plan and the Deferred Annual Bonus Plan. The awards, which included accrued dividends, were granted over ordinary shares with a nil purchase price.
A portion of the resulting shares was automatically sold on the London Stock Exchange to cover related tax liabilities, at a price of £3.684419 per share. The Performance Share Plan award was subject to performance conditions over a period ending on 31 December 2025 and must be retained until the shareholding requirement is met, and for Executive Directors in any event for two years after receipt. The awards are also subject to malus and clawback provisions.
Haleon plc reports that it has purchased 7,833,121 ordinary shares of £0.01 each for cancellation under its share buyback programme announced on 12 March 2026. The purchases were carried out on UK venues between 16 and 20 March 2026 at volume‑weighted average prices generally around the high‑370s to low‑390s pence per share.
After settlement of these transactions, Haleon’s registered share capital is 8,941,771,041 ordinary shares, of which 12,591,821 are held in treasury. This leaves 8,929,179,220 ordinary shares with voting rights, a figure shareholders can use for disclosure threshold calculations under the FCA’s transparency rules.
Haleon plc reported recent purchases of its own shares under a previously announced buyback programme. The company bought 2,749,486 ordinary shares of £0.01 each for cancellation on 12 and 13 March 2026 across the London Stock Exchange, CBOE UK venues and Aquis.
After these transactions settle, Haleon’s registered share capital will be 8,949,604,162 ordinary shares, including 43,651,673 held in treasury. This leaves 8,905,952,489 ordinary shares with voting rights, a figure shareholders can use for regulatory disclosure thresholds.
Haleon plc has published its 2025 Annual Report and Accounts & Form 20-F, together with the Notice of its 2026 Annual General Meeting. These documents are available on the company’s website and the Form 20-F is being filed with the SEC.
The 2026 AGM will be held as a virtual meeting at 3:00pm (BST) on 29 April 2026, with joining details set out in the AGM Notice. Shareholders can also request a free hard copy of the Annual Report, including the audited financial statements.
Haleon plc reported new share-based awards granted to its Chief Executive Officer and Chief Financial Officer under its long-term incentive and bonus deferral plans. On 12 March 2026, CEO Brian McNamara received conditional awards over 1,639,855 ordinary shares under the Performance Share Plan and 173,825 shares under the Deferred Annual Bonus Plan, both at nil cost. On the same date, CFO Dawn Allen received conditional awards over 712,784 shares under the Performance Share Plan and 95,513 shares under the Deferred Annual Bonus Plan, also at nil cost. The main Performance Share Plan awards are subject to performance conditions through 31 December 2028, are aligned with Haleon’s Directors’ Remuneration Policy, and are subject to malus and clawback provisions.
Haleon plc reported modestly lower 2025 revenue of £11,030m, slightly down from £11,233m in 2024, but delivered stronger profitability. Operating profit rose to £2,412m and profit after tax increased to £1,680m, lifting basic earnings per share to 18.6p from 15.8p.
Cash generation was solid, with net cash inflow from operating activities of £2,634m. The balance sheet strengthened as total liabilities fell to £16,146m and net assets grew to £16,484m. For 2025, dividends paid totalled £612m, and the Board proposes a further 4.9p final dividend.
The company highlights a focus on health and safety, with a 2025 reportable injury and illness rate of 0.14 per 100,000 hours and no fatalities. Cyber security remained a principal risk area, with a dedicated function, a CEO-led culture campaign, and no significant cyber incidents identified in 2025.
Haleon plc is starting a share buyback programme to repurchase its ordinary shares for up to an aggregate consideration of £500 million. The programme follows its 2025 preliminary full year results announcement and is aligned with its capital allocation priorities, including delivering attractive shareholder returns.
Haleon has signed an irrevocable agreement with HSBC Bank plc, which will independently decide the timing of purchases on the London Stock Exchange, CBoE Equities Europe, and Aquis, including during closed periods. The buyback begins immediately and will end no later than 19 August 2026.
Purchases before the 2026 Annual General Meeting will use the existing 2025 shareholder authority, and any later purchases will rely on authority sought at the 2026 AGM, if approved. All repurchased shares will be cancelled to reduce Haleon’s share capital, and there is no guarantee the full programme will be completed.
Haleon plc provided an update on its total voting rights and share capital. As at 28 February 2026, the company had 8,952,353,648 issued ordinary shares of £0.01 each, with 43,969,144 held as treasury shares. This leaves 8,908,384,504 ordinary shares carrying voting rights.
The company states that this voting-rights figure should be used by shareholders and others with notification obligations as the denominator when calculating whether they must disclose interests or changes in interests under the FCA's Disclosure Guidance and Transparency Rules.